Regeneron price target lowered to $1,000 from $1,100 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...
Fierce Biotech15h
Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Zacks Investment Research on MSN13h
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...
Amgen (AMGN) Receives a Buy from TD Cowen
TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...